The Stem Cell Processing Core provides for collection, processing, storage, transportation, infusion, and analysis of bone marrow and blood components. Most of the activities of their core are billed to the patient. Consolidation of these activities into one service assures a high level of quality control. In addition, this core provides services that are not billed to the patient, specifically the development of new cell processing techniques, extensive analysis of cell phenotypes by flow cytometric analysis (beyond what is necessary for quality control of the marrow of blood component), and collection of cells specifically for research purposes. This core will devote one laboratory technologist to the cell processing and analysis tasks described in this section. These tasks include 1) assisting in the development and validation of T-cell depletion techniques for bone marrow or blood stem cell components, 2) assisting in the analysis of the processed components, 3) performing flow cytometric analysis of marrow and blood stem cell components collected from unrelated donors, and 4) maintaining a database for use by the principal investigators of the projects supported by this core. This core will also provide for the collection of peripheral blood cells by apheresis in support of the projects studying the use of cytotoxic and helper T-cells for adoptive immunotherapy. The centralization of the handling of human blood and marrow samples in this laboratory facilitates the application of uniform standards of procedure and quality control. Furthermore, over the grant period new marrow, peripheral blood and cord blood procedures will be developed for clinical use, all of which must be subjected to uniform control of safety standards The Apheresis Unit and Cryobiology Laboratory are best suited to provide this monitoring at the most cost-effective rate.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA018029-22A1
Application #
6236406
Study Section
Project Start
1997-08-28
Project End
1997-11-30
Budget Start
1996-10-01
Budget End
1997-09-30
Support Year
22
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
Deegan, Anthony J; Talebi-Liasi, Faezeh; Song, Shaozhen et al. (2018) Optical coherence tomography angiography of normal skin and inflammatory dermatologic conditions. Lasers Surg Med 50:183-193
Leger, Kasey J; Baker, K Scott; Cushing-Haugen, Kara L et al. (2018) Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation. Cancer 124:1507-1515
Schmitt, Michael W; Pritchard, Justin R; Leighow, Scott M et al. (2018) Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias. Clin Cancer Res 24:5321-5334
Shaw, Bronwen E; Syrjala, Karen L; Onstad, Lynn E et al. (2018) PROMIS measures can be used to assess symptoms and function in long-term hematopoietic cell transplantation survivors. Cancer 124:841-849
Jamani, Kareem; Onstad, Lynn E; Bar, Merav et al. (2018) Quality of Life of Caregivers of Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 24:2271-2276
Ogimi, Chikara; Xie, Hu; Leisenring, Wendy M et al. (2018) Initial High Viral Load Is Associated with Prolonged Shedding of Human Rhinovirus in Allogeneic Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 24:2160-2163
Salter, Alexander I; Pont, Margot J; Riddell, Stanley R (2018) Chimeric antigen receptor-modified T cells: CD19 and the road beyond. Blood 131:2621-2629
Lee, Stephanie J; Nguyen, Tam D; Onstad, Lynn et al. (2018) Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:555-562
Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313
Armenian, Saro H; Yang, Dongyun; Teh, Jennifer Berano et al. (2018) Prediction of cardiovascular disease among hematopoietic cell transplantation survivors. Blood Adv 2:1756-1764

Showing the most recent 10 out of 1845 publications